Displaying drugs 14451 - 14475 of 15143 in total
P140K methylguanine-DNA-methyltransferase mutant CD34+ cells
Investigational
SRX-1177
Investigational
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and …
Activated natural killer cell therapy
Investigational
Adenovirus/PNP
Investigational
ETBX-041
Investigational
Carlecortemcel-L
Investigational
PBCAR269A
Investigational
PBCAR20A
Investigational
P-2045 Re-188
Investigational
ALM201
ALM201 is an anti-angiogenic synthetic peptide identified from the endogenous human protein, FKBPL. It is being investigated in the treatment of various cancers.
Investigational
KAb201
Investigational
hu3S193
Investigational
Pritumumab
Investigational
Tamrintamab pamozirine
Tamrintamab pamozirine is an antibody-drug conjugate targeted against DPEP3.
Investigational
JCAR014
Investigational
Letetresgene autoleucel
Investigational
M-032
Investigational
Zevorcabtagene autoleucel
Investigational
Galinpepimut-S
Investigational
ST101 peptide
ST101 is a cell-penetrating peptide that disrupts the protein-protein interactions driving ATF5-regulated gene transcription.
Investigational
ONCOS-102
Investigational
GVAX
GVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine.
Investigational
OriCar-017
Investigational
Displaying drugs 14451 - 14475 of 15143 in total